Asymmetry of Muscle Activation in Multiple Sclerosis

Brief summary Our research uses advanced neuroscience techniques to explore how the nervous system controls muscles in multiple sclerosis, with a particular focus on muscle weakness, fatigue and sensorimotor function. Ultimately, we aim to identify how specific neurophysiological changes due to MS influence movement and disability (e.g. mobility impairment) so that future treatments can be […]

The Multiple Sclerosis Australian Women’s Midlife Years (MS-AMY) Study

Researchers at Monash University are undertaking a study to understand the physical health and psychological, sexual and socioeconomic wellbeing of Australian midlife women living with MS.  The team wants to assess the contribution of common midlife circumstances, including the impact of menopause, on the quality of life of women living with MS. Surprisingly very little […]

ACT-Sydney Multiple Sclerosis (MS) cohort study

As part of the Our Health in Our Hands (OHIOH) project, researchers at the Australian National University and Sydney Adventist Hospital are working together to improve the clinical management and overall health and wellbeing of people living with multiple sclerosis (MS). In this study we are recruiting people with MS as well as people who […]

Anxiety in Multiple Sclerosis

We are interested in identifying psychological factors that contribute to the development and maintenance of anxiety in individuals with MS. We are also interested in comparing these factors to those without an illness. Participants will be requested to fill out an online questionnaire at three different time points. Time 1: Fill out an ~30min questionnaire. […]

Reducing the frequency of Autoimmune adverse events in the treatment of Multiple sclerosis with alemtuzumab using B-celL dEpletion (RAMBLE): a phase II, randomised, placebo-controlled clinical trial

To reduce the occurrence of autoimmune adverse events from the treatment of multiple sclerosis (MS) with alemtuzumab through the subsequent targeted use of rituximab. The hypothesis to be tested is that rituximab therapy following alemtuzumab treatment for MS will reduce the frequency of autoimmune adverse events. If this strategy proves to be safe and is […]